Abstract
Critical quality attributes (CQAs) play an important role in demonstrating Q1, Q2, and Q3 equivalence of topical products between the test and reference products. In vitro testing is one of the CQAs that is predominantly used in the correlation of Q3 microstructure to product performance. Two types of in vitro tests are typically employed to understand the microstructure, namely, in vitro release tests (IVRT) and in vitro permeation tests (IVPT). IVRT provides information on the release of the drug from a formulation and IVPT provides information on the permeation of the drug through the skin. Both can be influenced by the type of dosage form that includes gels, creams, ointments, and lotions. Each of the dosage forms has a different matrix that varies in complexity and affects the IVRT/IVPT differently. Different microstructure parameters influence release rates and some of these include: viscosity and rheological properties, globule and particle sizes, pH, phase homogeneity, polymorphism, etc. Excipients have an influence on microstructure properties: for example, the type and grade of the excipient, different solvents, co-solvents, penetration enhancers, preservatives, coloring agents, and fragrances. Microstructure properties are also greatly influenced by the critical processing parameters (CPPs). Examples are mixing time, cooling/heating, mixer type, mixing temperature, speed and duration, and hold times at various process stops. IVRT plays a very important role in evaluating any post-approval change in process that can impact product quality and performance. FDA has issued the SUPAC-SS guidance to identify the different levels of process changes and how IVRT should be conducted to evaluate the impact. The various process level changes and what methodology should be adopted are discussed. In summary, this chapter provides an introduction to in vitro release and permeation testing and how this test can be a tool in evaluating Q3 microstructure.
Keywords
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
M. Alberti, Y. Dancik, G. Sriram, B. Wu, Y.L. Teo, Z. Feng, M. Bigliardi-Qi, R.G. Wu, Z.P. Wang, P.L. Bigliardi, Multi-chamber microfluidic platform for high-precision skin permeation testing. Lab Chip 17, 1625–1634 (2017)
W.L. Au, M. Skinner, I. Kanfer, Comparison of tape stripping with the human skin blanching assay for the bioequivalence assessment of topical clobetasol propionate formulations. J. Pharm. Pharma. Sci. 13(1), 11–20 (2010)
B. Balazs, G. Vizseralek, S. Berko, M. Budai-Szucs, A. Kelemen, B. Sinko, K. Takacs-Novak, P. Szabo-Revesz, E. Csanyi, Investigation of the efficacy of transdermal penetration enhancers through the use of human skin and a skin mimic artificial membrane. J. Pharm. Sci. 105, 1134–1140 (2016)
R. Baynes, J. Riviere, T. Franz, N. Monteiro-Riviere, P. Lehman, M. Peyrou, P.L. Toutain, Challenges obtaining a biowaiver for topical veterinary dosage forms. J. Vet. Pharmacol. Ther. 35(Suppl 1), 103–114 (2012)
M. Bodenlenz, C. Ho¨fferer, C. Magnes, et al., Dermal PK/PD of a lipophilic topical drug in psoriatic patients by continuous intradermal membrane-free sampling. Eur. J. Pharm. Biopharm 81(3), 635–641 (2012)
M. Bodenlenz, B. Aigner, C. Dragatin, et al., Clinical applicability of dOFM devices for dermal sampling. Skin Res. Technol. 19(4), 474–483 (2013)
M. Bodenlenz, K.I. Tiffner, R. Raml, T. Augustin, C. Dragatin, T. Birngruber, D. Schimek, G. Schwagerlez, T.R. Pieber, S.G. Raney, I. Kanfer, F. Sinner, Open flow microperfusion as a dermal pharmacokinetic approach to evaluate topical bioequivalence. Clin Pharmacokinetics 56, 91–98 (2017)
F. Bonina, C. Puglia, D. Trombetta, M.C. Dragani, M.M. Gentile, G. Clavenna, Vehicle effects on in vitro skin permeation of thiocolchicoside. Pharmazie 57, 750–752 (2002)
R.-K. Chang, A. Raw, R. Lionberger, L. Yu, Generic development of topical dermatologic products: Formulation development, process development, and testing of topical dermatologic products. AAPS J. 15(1), 41–52 (2013a)
R.-K. Chang, A. Raw, R. Lionberger, L. Yu, Generic development of topical dermatologic products, part II: Quality by Design for Topical Semisolid Products. AAPS J. 15(3), 674–683 (2013b)
H.V. Chavda, Qbd in developing topical dosage forms. Ely. J. Pharm. Res. 2(1), 1–2 (2016)
Y.W. Chien, Chapter 2: Developmental Concepts & Practice in Transdermal Therapeutic Systems, in Transdermal Controlled Systemic Medications, (Marcel Dekker, New York, 1987), pp. 44–47
J.M. Christensen, M.C. Chuong, H. Le, L. Pham, E. Bendas, Hydrocortisone diffusion through synthetic membrane, mouse skin, and Epiderm cultured skin. Arch. Drug Inform. 4, 10–21 (2011)
S.E. Cross, M.S. Roberts, Use of in vitro human skin to model and predict the effect of changing blood flow on the flux and retention of topically applied solutes. J. Pharm. Sci. 97(8), 3442–3450 (2008)
C. Dragatin, F. Polus, M. Bodenlenz, et al., Secukinumab distributes into dermal interstitial fluid of psoriasis patients as demonstrated by open flow microperfusion. Exp Dermatol 25(2), 157–159 (2016)
D. Dupuis, R. Rougier, R. Roguet, C. Lotte, The measurement of the stratum corneum reservoir: A simple method to predict the influence of vehicles on in vivo percutaneous absorption. Br. J. Dermatol. 115, 233–238 (1986)
B.A. Elewski, Percutaneous absorption kinetics of topical metronidazole formulations in vitro in the human cadaver skin model. Adv Ther 24(2), 239–246 (2007)
Food & Drug Administration, Product Specific Guidance for Generic Drug Development (2016). https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM428195.pdf
Food and Drug Administration, Guidance for Industry: Topical Dermatologic Drug Product NDAs and ANDAs In Vivo Bioavailability, Bioequivalence, in Vitro Release, and Associated Studies (1998)
Food and Drug Administration (FDA), Guidance for Industry: PAT — A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance (Food and Drug Administration (FDA), Rockville, MD, 2004)
Food and Drug Administration (FDA), Role of Models in the Quality by Design (QbD) Paradigm: Regulatory Perspective (2011). http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4241b1-02-22-fda-qbd%20obp2%20304_haury.pdf
Fowler M, Quality by Design (QbD) Approach to Generic Transdermal or Topical Product Development (2015). Available at: http://www.americanpharmaceuticalreview.com/Featured-Articles/172883-Quality-by-Design-QbD-Approach-to-Generic-Transdermal-or-Topical-Product-Development
T.J. Franz, On the relevance of in vitro data. J. Invest. Dermatol. 64, 190–195 (1975)
P.O. Fritsch, G. Gschnait, G. Kaaserer, et al., PUVA suppresses the proliferative stimulus produced by stripping on hairless mice. J. Invest. Dermatol. 73(2), 188–190 (1979)
S.J. Gallagher, C.M. Heard, Solvent content and macroviscosity effects on the in vitro transcutaneous delivery and skin distribution of ketoprofen from simple gel formulations. Skin Pharmacol. Physiol. 18, 186–194 (2005)
S.J. Gallagher, L. Trottet, C.M. Heard, Ketoprofen: Release from, permeation across and rheology of simple gel formulations that simulate increasing dryness. Int. J. Pharm. 268, 37–45 (2003)
K. Goebel, M.E.O. Sato, D.F. Souza, S. Murakami, I.F. Andreazza, In vitro release of diclofenac diethylamine from gels: Evaluation of generic semisolid drug products in Brazil. Braz. J. Pharm. Sci. 49(2), 211–220 (2013)
Z. Guerol, S. Hekimoglu, R. Demirdamar, M. Sumnu, Percutaneous absorption of ketoprofen. I. In vitro release and percutaneous absorption of ketoprofen from different ointment bases. Pharm. Acta Helv. 71, 205–212 (1996)
J. Hadgraft, R.H. Guy, Feasibility Assessment in Topical and Transdermal Drug Delivery: Mathematical Models and In Vitro Studies, in Transdermal Drug Delivery, ed. by R. Guy, J. Hadgraft, 2nd edn., (Marcel Dekker, New York, 2003), pp. 1–23
J. Hadgraft, M. Whitefield, P.H. Rosher, Skin penetration of topical formulations of ibuprofen 5%: An in vitro comparative study. Skin Pharmacol. Appl. Ski. Physiol. 16, 142 (2003)
C. Herkenne, A. Naik, Y.N. Kalia, J. Hadgraft, R.H. Guy, Ibuprofen transport into and through skin from topical formulations: In vitro-in vivo comparison. J. Invest. Dermatol. 127, 135–142 (2007)
T. Higuchi, Rate of release of medicaments from ointment bases containing drugs in suspension. J. Pharm. Sci. 50, 874–875 (1961)
http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q8_R1/Step4/Q8_R2_Guideline.pdf (2009)
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline, Quality Risk Management– Q9 (November 2005). Available at: www.ich.org
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline, Pharmaceutical Quality Systems–Q10 (June 2008), Available at: www.ich.org. Accessed 21 Nov 2014
International Conference on Harmonization (ICH): Implementation of ICH Q8, Q9, Q10 (2010). https://www.ispe.org/index.php/ci_id/6286/la_id/1.htm. (Accessed June 2016)
International Conference on Harmonization (ICH) Q8(R2): Pharmaceutical Development (2009). http://www.ich.org/products/guidelines/quality/article/quality-guidelines.html
J. Jain, Bioequivalence of topical dosage forms. J. Pharm. 2(2), 1–2 (2014)
A. Jankowski, R. Dyja, B. Sarecka-Hujar, Dermal and transdermal delivery of active substances from semisolid bases. Indian J. Pharm. Sci. 79(4), 488–500 (2017)
J.M. Juran, The Quality Trilogy: A Universal Approach to Managing for Quality. Quality Progress, 19(8), 19–24 (1986)
J.M. Juran, Juran on Quality by Design: The New Steps for Planning Quality into Goods and Services (Free Press, New York, 1992)
M. Kietzmann, B. Blume, Percutaneous absorption of betamethasone from different formulations using the isolated perfused bovine udder. In Vitro Toxicol 10, 11–15 (1997)
R.R. Klein, J.Q. Tao, S. Wilder, K. Burchett, Q. Bui, K.D. Thakker, Development of an in vitro release test (IVRT) for a vaginal microbicide gel. Dissolut. Technol. 17(4), 6–10 (2010)
Y.S. Krishnaiah, X. Xu, Z. Rahman, Y. Yang, U. Katragadda, R. Lionberger, J.R. Peters, K. Uhl, M.A. Khan, Development of performance matrix for generic product equivalence of acyclovir topical creams. Int. J. Pharm. 475(1–2), 110–122 (2014a)
Y.S. Krishnaiah, N. Kamal, N. Pavurala, X. Xu, M.A. Khan, Effect of Aqueous Phase pH on the In Vitro Performance of Acyclovir Topical Creams AAPS poster, AAPS Annual Meeting and Exposition, San Diego, CA (2014b)
Y.S. Krishnaiah, N. Kamal, N. Pavurala, X. Xu, M.A. Khan, Development of Discriminatory In Vitro Release Test (IVRT) and In Vitro Permeation Test (IVPT) Methods for Acyclovir Topical Cream Using Quality by Design Approach (AAPS poster, San Diego, CA, 2016)
P.A. Lehman, S.G. Raney, T.J. Franz, Percutaneous absorption in man: in vitro-in vivo correlation. Skin Pharmacol. Physiol. 24(4), 224–230 (2011)
R. Lionberger, S. Lee, A. Raw, L. Yu, Quality by design: Concepts for ANDAs. AAPS J. 10(2), 268–276 (2008)
N.A. Megrab, A.C. Williams, B.W. Barry, Oestradiol permeation through human skin and silastic membrane: effects of propylene glycol and supersaturation. J. Control. Release 36, 277–294 (1995)
P. Minghetti, A. Casiraghi, F. Cilurzo, L. Montanari, M. Marazzi, L. Falcone, V. Donati, Comparison of different membranes with cultures of keratinocytes from man for percutaneous absorption of nitroglycerine. J. Pharm. Pharmacol. 51, 673–678 (1999)
S.N. Murthy, Characterizing the critical quality attributes and in vitro bioavailability of acyclovir and metronidazole topical products. Perspectives in Percutaneous Penetration Conference 2016, 2014
C. Nagelreiter, S. Raffeiner, C. Geverhofer, V. Klang, C. Valenta, Influence of drug content, type of semi-solid vehicle and rheological properties on the skin penetration of the model drug fludrocortisone acetate. Int. J. Pharm. 448(1), 305–312 (2013)
G.M. Nemecek, A.D. Dayan, Safety evaluation of human living skin equivalents. Toxicol. Pathol. 27, 101–103 (1999)
V.E. Nwoko, Semi Solid dosage Forms Manufacturing: Tools, Critical Process Parameters, Strategies, Optimization and Validation. Sch. Acad. J. Pharm. 3, 153–161 (2014)
D.W. Osborne Compositions for topical application of therapeutic agents. US patent 6,620,435 B1, assignee ViroTex Coroporation (2003)
D.W. Osborne, Impact of quality by design on topical product excipient suppliers, part I: A drug Manufacturer’s perspective. Pharm. Technol. 40(10), 38–43 (2015)
C. Puglia, P. Blasi, A. Rizza, F. Schoubben, F. Bonina, C. Rossi, M. Ricci, Lipid nanoparticles for prolonged topical delivery: An in vitro and in vivo investigation. Int. J. Pharm. 357, 295–304 (2008)
S.A. Rabbani, Approaches for bioequivalence assessment of topical dermatological formulations. Adv. Bioequival. Bioavail. 1(1), 1–3 (2018)
F.S. Radulescu, D.S. Miron, Physicochemical characterization of acyclovir topical semisolid dosage forms towards TCS validation. 3rd FDA/PQRI Conference on Advancing Product Quality, 22-24 Mar2017
V. Rai, J. Terebetski, S. Silva, B. Michniak-Kohn, Human Skin Equivalents (HSEs) as an alternative for transdermal permeation, phototoxicity and cytotoxicity studies. Transdermal 2(3), 5–8 (2010)
S. Raney, Strategies to improve patient access to high quality topical products AAPS workshop dermatological drug products: developmental & regulatory considerations, 12 Nov 2017a
S. Raney, In vitro characterization of topical semisolid dosage forms. Presented at the 3rd PQRI/FDA Conference on Advancing Product Quality (2017b)
Roberts MS, Mohammed Y, Namjoshi S, Jung N, Chaitanya K, Cheruvu S, Windbergs M, Liu X, Benson HAE, Naegel A, Wittum R, Stokes J, Shewan H, Ghosh P, Ramezanli T, Raney S, Grice JE, Correlation of physicochemical characteristics and in vitro permeation test (IVPT) results for acyclovir and metronidazole topical products. FDA Workshop on Bioequivalence Testing of Topical Drug Products, 2017
F.P. Schmook, J.G. Meingasser, A. Billich, Comparison of human skin or epidermis models with human and animal skin in in-vitro percutaneous absorption. Int. J. Pharm. 215, 51–56 (2001)
V.P. Shah, J.S. Elkins, R.L. Williams, Evaluation of the test system used for in vitro release of drugs for topical dermatological drug products. Pharm. Dev. Technol. 4, 377–385 (1999)
A.H. Shojaei, B. Berner, X.L. Li, Transbuccal delivery of acyclovir: I in vitro determination of routes of buccal transport. Pharm. Res. 15, 1182–1118 (1998)
C. Shukla, E.D. Bashaw, G. Stagni, E. Benfeldt, Applications of dermal microdialysis: A review. J. Drug Deliv. Sci. Technol. 24(3), 259–269 (2014)
O. Siddiqui, M.S. Roberts, A.E. Polack, The effect of iontophoresis and vehicle pH on the in-vitro permeation of lignocaine through human stratum corneum. J. Pharm. Pharmacol. 37(10), 732–735 (1985)
P.J. Sinko, Diffusion, in Martin’s Physical Pharmacy and Pharmaceutical Sciences, ed. by P. J. Sinko, 5th edn., (Lippincott Williams and Wilkins, Philadelphia, PA, 2006), pp. 301–335
A. Sivaraman, A.K. Banga, Quality by design approaches for topical dermatological dosage forms. Res. Rep. Transdermal Drug Deliv. 4, 9–21 (2015)
R.K. Subedi, S.Y. Oh, M.K. Chun, H.K. Choi, Recent advances in transdermal drug delivery. Arch. Pharm. Res. 33, 339–351 (2010)
K.D. Thakker, W.H. Chern, Development and validation of in vitro release tests for semisolid dosage forms – Case study. Dissolut. Technol. 10(2), 10–15 (2003)
K.I. Tifffner, I. Kanfer, T. Augustin, R. Raml, S.G. Raney, A comprehensive approach to quality and validate the essential parameters of an in vitro release test (IVRT) method for acyclovir cream, 5%. Int. J. Pharm. 535, 217–227 (2018)
K. Tojo, P.R. Keshary, Y.W. Chien, Drug permeation through skin from matrix-type drug delivery systems. Chem. Engineer. J. 32(3), B57–B64 (1986)
J.C. Tsia, S.A. Chuang, M.Y. Hsu, H.M. Sheu, Distribution of salicylic acid in human stratum corneum following topical application in vivo: A comparison of six different formulations. Int. J. Pharm. 188, 145–153 (1999)
U.S. USP chapter <1724> Semisolid drug products – performance tests, in: USP 40, pp 2055–2067 (2017)
U.S. FDA, Guidance for industry nonsterile semisolid dosage forms, scale-up and Post-approval changes: chemistry, manufacturing, and controls; in vitro release testing and in vivo bioequivalence documentation (SUPAC-SS). Guidance for Industry. US. (1997)
U.S. FDA. Formal Meetings Between FDA and ANDA Applicants of Complex Products Under GDUFA, Guidance for Industry, draft guidance (2017)
U.S. FDA, Product-Specific Guidances for Generic Product Development (2019)
U.S. Food and Drug Administration Center for Drug Evaluation and Research (CDER), Manual of Policies and Procedures MAPP 5016.1. Applying ICH Q8(R2), Q9, and Q10 Principles to CMC Review. February 2011. Available at: www.fda.gov. Accessed 21 Nov 2014.
J. Vonguru, R. Gilman, R. Klein, D.M. Mattocks, K.D. Thakker, Developing in vitro release testing (IVRT) methods for petrolatum based semi-solid dosage forms. Abstract submission, AAPS (2015)
C.K. Wang, C.F. Nelson, A.M. Brinkman, A.C. Miller, W.K. Hoffler, Spontaneous cell sorting of fibroblasts and keratinocytes creates an organotypic human skin equivalent. J Invest Dermatol 114, 674–680 (2000)
J. Wolf, Die innere Struktur der Zellen des Straum desquamans der mensschlichen Epidermis. Z mikranat Forsch 46, 170–202 (1939)
X. Xu, M. Al-Ghabeish, Y.S. Krishnaiah, Z. Rahman, M.A. Khan, Kinetics of drug release from ointments: Role of transient-boundary layer. Int J Pharm. 494, 31–39 (2015)
L.X. Yu, G. Amidon, M.A. Khan, S.W. Hoag, J. Polli, G.K. Raju, J. Woodcock, Understanding pharmaceutical quality by design. APPS J 16(4), 771–783 (2014)
Z. Zheng, B. Michniak-Kohn, Tissue engineered human skin equivalents. Pharmaceutics ISSN 1999–4923 (2012). www.mdpi.com/journal/pharmaceutics; https://doi.org/10.3390/pharmaceutics4010026, 4: 26–41.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 AAPS (American Association of Pharmaceutical Scientists)
About this chapter
Cite this chapter
Raghavan, L., Brown, M., Michniak-Kohn, B., Ng, S., Sammeta, S. (2019). In Vitro Release Tests as a Critical Quality Attribute in Topical Product Development. In: Langley, N., Michniak-Kohn, B., Osborne, D. (eds) The Role of Microstructure in Topical Drug Product Development. AAPS Advances in the Pharmaceutical Sciences Series, vol 36. Springer, Cham. https://doi.org/10.1007/978-3-030-17355-5_2
Download citation
DOI: https://doi.org/10.1007/978-3-030-17355-5_2
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-17354-8
Online ISBN: 978-3-030-17355-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)